Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Vir Biotechnology, Inc.
Vir Biotechnology, Inc.
Memorial Sloan Kettering Cancer Center
Hanmi Pharmaceutical Company Limited
M.D. Anderson Cancer Center
ModernaTX, Inc.
Genmab
Kumquat Biosciences Inc.
Treeline Biosciences, Inc.
Merck Sharp & Dohme LLC
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Teva Branded Pharmaceutical Products R&D, Inc.
Royal Marsden NHS Foundation Trust
Daiichi Sankyo
Chong Kun Dang Pharmaceutical
Gustave Roussy, Cancer Campus, Grand Paris
Inimmune Corporation
Abalos Therapeutics GmbH
Novartis
D2M Biotherapeutics Inc.
Hanmi Pharmaceutical Company Limited
Abramson Cancer Center at Penn Medicine
Oncomatryx Biopharma S.L.
Cullinan Therapeutics Inc.
Seattle Children's Hospital
Aptabio Therapeutics, Inc.
Amgen
Zai Lab (Hong Kong), Ltd.
M.D. Anderson Cancer Center
Incyte Corporation
Merck Sharp & Dohme LLC
Genmab
Providence Health & Services
DynamiCure Biotechnology
University of Chicago
Turnstone Biologics, Corp.
Cullinan Therapeutics Inc.
Five Prime Therapeutics, Inc.
Sotio Biotech Inc.
Eucure (Beijing) Biopharma Co., Ltd
NGM Biopharmaceuticals, Inc
ImmunOs Therapeutics AG
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
CytomX Therapeutics
Xencor, Inc.
University of Chicago
Immune-Onc Therapeutics
NGM Biopharmaceuticals, Inc
Adagene Inc
Pierre Fabre Medicament
New Beta Innovation Limited